Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11602
Full metadata record
DC FieldValueLanguage
dc.contributor.authorYeung, Yvonneen
dc.contributor.authorTebbutt, Niall Cen
dc.date.accessioned2015-05-16T01:13:05Z
dc.date.available2015-05-16T01:13:05Z
dc.date.issued2012-10-31en
dc.identifier.citationExpert Review of Anticancer Therapy 2012; 12(10): 1263-73en
dc.identifier.govdoc23113577en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/11602en
dc.description.abstractBevacizumab is a humanized monoclonal antibody to VEGF-A, an important therapeutic target through its proangiogenic effects on a variety of tumors. Bevacizumab has demonstrated clinically meaningful benefit in conjunction with chemotherapy for patients with metastatic colorectal cancer as well as other tumor types. Bevacizumab is a well-tolerated therapy with regard to toxicity, in keeping with its biological vascular effect. In this era of personalized medicine, current Phase II and III trials are further defining its role at various stages of metastatic disease and the optimal sequencing with cytotoxic and other targeted agents to achieve further improvements in patient outcome. Translational research for biomarker discovery and validation and further study into mechanisms of resistance are essential for future development and sustained benefit with this class of therapeutic agents.en
dc.language.isoenen
dc.subject.otherAngiogenesis Inhibitors.adverse effects.pharmacokinetics.pharmacology.therapeutic useen
dc.subject.otherAnimalsen
dc.subject.otherAntibodies, Monoclonal, Humanized.adverse effects.pharmacokinetics.pharmacology.therapeutic useen
dc.subject.otherClinical Trials as Topicen
dc.subject.otherColorectal Neoplasms.blood supply.drug therapy.metabolismen
dc.subject.otherDrug Resistance, Neoplasmen
dc.subject.otherHumansen
dc.subject.otherRandomized Controlled Trials as Topicen
dc.subject.otherTumor Markers, Biological.metabolismen
dc.titleBevacizumab in colorectal cancer: current and future directions.en
dc.typeJournal Articleen
dc.identifier.journaltitleExpert review of anticancer therapyen
dc.identifier.affiliationLudwig Institute for Cancer Research, Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1586/era.12.104en
dc.description.pages1263-73en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/23113577en
dc.type.austinJournal Articleen
local.name.researcherTebbutt, Niall C
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.